BioSpace News Archive

Strategic focus of immuno-oncology (I-O) portfolio on modulation of tumor microenvironment to enhance T cell influx and activity in immune excluded solid tumors, aspects that immune checkpoint inhibitors do not address. - Preclinical Proof of Concept for Company’s priority I-O program, aiming at depleting regulatory T cells (Tregs) by targeting C-C motif chemokine re

Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at a public offering price of $16.00 per share

Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced the pricing of an underwritten public offering of 20,833,322 shares of common stock or common stock equivalents

- INNO2VATE data presented at American Society of Nephrology Kidney Week 2020 Reimagined - Presentation expands on previously announced positive top-line data showing vadadustat achieved clear and consistent results across primary and secondary efficacy and safety endpoints - Company on track to submit New Drug Application - Company to host investor briefing webcast at 4:10 p.m. ET on October 23, 2020

MyMeds&Me, a leading provider of drug safety software to transform the end-to-end pharmacovigilance process, have today announced that Aurinia Pharmaceuticals Inc. (Aurinia) has selected the Reportum QuickStart platform to streamline the capture, processing and management of safety data for the investigational drug voclosporin, following recent positive Phase 3 results.

Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease will webcast an investor update at the virtual VIVA20 on Saturday, November 7 at 11:00 a.m. eastern time.

-- GFB-887, a first-in-class highly potent and selective inhibitor of the TRPC5-Rac1 pathway, was well-tolerated in single ascending doses -- -- GFB-887 induced dose-dependent reductions in urinary Rac1, demonstrating target engagement -- -- TRPC5-Rac1 pathway overactivation is key cause of disease in substantial portion of patients with focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN) --

- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released after market close on Thursday, November 5, 2020. Starting at 4:30 p.m. EST, Coherus’ management team will host a conference call to discuss financial results and provide a general business update. After releasing third quarter financial results, the Company will post them on the Coherus website at https:/

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2020 financial results on Thursday, November 5, 2020. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international caller

Part of the Prelude Network, Advanced Fertility Center of Chicago Expands Clinical Staff with Board Certified OB/GYN, Reproductive Endocrinologist